Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of “Moderate Buy” from Analysts

Kodiak Sciences Inc. (NASDAQ:KOD) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $35.4286.

A number of equities analysts have recently issued reports on the company. UBS Group increased their target price on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. bought a new stake in shares of Kodiak Sciences in the 4th quarter worth about $11,440,000. Invesco Ltd. lifted its holdings in Kodiak Sciences by 454.1% during the 4th quarter. Invesco Ltd. now owns 555,073 shares of the company’s stock valued at $15,520,000 after purchasing an additional 454,894 shares during the last quarter. Ikarian Capital LLC boosted its position in Kodiak Sciences by 73.9% in the fourth quarter. Ikarian Capital LLC now owns 719,787 shares of the company’s stock valued at $20,125,000 after buying an additional 305,946 shares in the last quarter. Virtus Investment Advisers LLC acquired a new position in Kodiak Sciences in the fourth quarter valued at about $312,000. Finally, Wellington Management Group LLP grew its stake in Kodiak Sciences by 304.7% during the fourth quarter. Wellington Management Group LLP now owns 473,796 shares of the company’s stock worth $13,247,000 after buying an additional 356,737 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences News Roundup

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Company reported advancing pipeline and strong Phase III data for Zenkuda that management highlighted alongside Q4/2025 results — this progress and accelerated regulatory planning support upside expectations for KOD. Kodiak Announces Q4 and FY2025 Results
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $58 price target even as it trimmed forecasts — that continued analyst endorsement can provide investor support and a clear upside reference point.
• Neutral Sentiment: Q4 results showed a wider-than-expected loss, but commentary focused investor attention on pipeline milestones rather than only near-term P&L metrics. Zacks: Q4 Loss Wider Than Expected
• Negative Sentiment: Multiple analysts (Lifesci Capital and HC Wainwright) cut near-term EPS estimates across Q1–Q4 2026 and lowered FY2026–FY2029/2030 forecasts — these downward revisions increase short-term earnings uncertainty and can pressure the stock. (Market commentary and analyst notes issued April 1)
• Negative Sentiment: Some cuts are large and extend into multi-year forecasts (HC Wainwright cut FY2026–FY2029/2030 estimates; Lifesci trimmed FY2026), signaling analysts see a longer recovery path to profitability — this raises risk for investors focused on near-term fundamentals.

Kodiak Sciences Stock Down 5.1%

NASDAQ KOD opened at $40.63 on Friday. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $45.60. The stock has a market cap of $2.51 billion, a P/E ratio of -9.41 and a beta of 2.39. The company’s 50-day simple moving average is $26.08 and its 200 day simple moving average is $22.62.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). Research analysts anticipate that Kodiak Sciences will post -3.45 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.